| symbol |
VRML |
|---|
| 会社名 | Vermillion Inc （バ―ミリオン） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Biotechnology: In Vitro_In Vivo Diagnostic Substances
|
|---|
| 業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Vermillion Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to in addition to a physician's clinical assessment of a woman with a pelvic mass identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2 500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans. バ―ミリオンは、米国の診断検査プロバイダ―。主に婦人科癌および関連疾患の患者向けの医療検査の発見、開発、商品化に従事する。主要製品OVA1は、ソフトウェアアルゴリズム及び血液検査を統合卵巣癌試験システムで、悪性卵巣腫瘍の識別検査。本社はテキサス州オ―スティン。 Vermillion, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.
|
|---|
| 本社所在地 | 12117 Bee Caves Road Building Three Suite 100 Austin TX 78738 USA |
|---|
| 代表者氏名 | James T. LaFrance James T. LaFrance |
|---|
| 代表者役職名 | Chairman of the Board 取締役会会長 |
|---|
| 電話番号 | +1 512-519-0400 |
|---|
| 設立年月日 | 34304 |
|---|
| 市場名 | NASDAQ Small Cap |
|---|
| ipoyear | ―年 |
|---|
| 従業員数 | 40人 |
|---|
| url | www.vermillion.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/vrml |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -10.55000 |
|---|
| 終値（lastsale） | 0.64 |
|---|
| 時価総額（marketcap） | 48175520.64 |
|---|
| 時価総額 | 時価総額（百万ドル） 35.76280 |
|---|
| 売上高 | 売上高（百万ドル） 2.85400 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 23.20180 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -12.30500 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Vermillion Inc. revenues decreased 16% to $1.4M. Net loss increased 17% to $5.9M. Revenues reflect Product decrease of 19% to $1.2M. Higher net loss reflects Sales and Marketing - other increase of 32% to $2.6M (expense) General and administrative increase of 3% to $2.2M (expense) Other income (expense) net increase of 56% to $14K (expense). |
|---|